Floatz logo

snk02

Pathologically Confirmed Cancer Refractory to Conventional Therapy

NKGen Biotech, Inc.Cell therapyPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

180 Active assets in the Pathologically Confirmed Cancer Refractory to Conventional Therapy cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 50 →

Same molecule, other indications

snk02 is also rated in:

cancerDormant
CC
Indicative ·
47 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
Solid Tumor, AdultDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →